S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

$2.16
-0.08 (-3.57%)
(As of 09:34 AM ET)
Today's Range
$2.16
$2.48
50-Day Range
$1.35
$2.24
52-Week Range
$0.49
$2.48
Volume
16.61 million shs
Average Volume
3.41 million shs
Market Capitalization
$452.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Akebia Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.9% Upside
$4.50 Price Target
Short Interest
Healthy
4.84% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.43mentions of Akebia Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$300,598 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.27) to ($0.19) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

180th out of 939 stocks

Pharmaceutical Preparations Industry

72nd out of 435 stocks

AKBA stock logo

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

AKBA Stock Price History

AKBA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
U.S. FDA approves Akebia's anemia drug
Akebia Awaits FDA Word On Second Crack At Vadadustat
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Recap: Akebia Therapeutics Q4 Earnings
Akebia Therapeutics earnings: here's what Wall Street expects
Earnings Preview For Akebia Therapeutics
See More Headlines
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AKBA
Employees
204
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.50
High Stock Price Target
$5.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+100.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-51,920,000.00
Pretax Margin
-26.68%

Debt

Sales & Book Value

Annual Sales
$194.62 million
Book Value
($0.16) per share

Miscellaneous

Free Float
201,332,000
Market Cap
$468.99 million
Optionable
Optionable
Beta
0.78
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives


AKBA Stock Analysis - Frequently Asked Questions

Should I buy or sell Akebia Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKBA shares.
View AKBA analyst ratings
or view top-rated stocks.

What is Akebia Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month target prices for Akebia Therapeutics' stock. Their AKBA share price targets range from $4.00 to $5.00. On average, they expect the company's stock price to reach $4.50 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for AKBA
or view top-rated stocks among Wall Street analysts.

How have AKBA shares performed in 2024?

Akebia Therapeutics' stock was trading at $1.24 on January 1st, 2024. Since then, AKBA shares have increased by 80.6% and is now trading at $2.24.
View the best growth stocks for 2024 here
.

Are investors shorting Akebia Therapeutics?

Akebia Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 10,130,000 shares, an increase of 24.9% from the February 29th total of 8,110,000 shares. Based on an average daily volume of 3,010,000 shares, the short-interest ratio is presently 3.4 days.
View Akebia Therapeutics' Short Interest
.

When is Akebia Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our AKBA earnings forecast
.

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) posted its earnings results on Thursday, March, 14th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.04). The biopharmaceutical company earned $56.20 million during the quarter, compared to the consensus estimate of $55.64 million. During the same period in the prior year, the company earned ($0.04) earnings per share.

What ETF holds Akebia Therapeutics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio.

What is John Butler's approval rating as Akebia Therapeutics' CEO?

28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Akebia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Who are Akebia Therapeutics' major shareholders?

Akebia Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.83%), Vanguard Group Inc. (3.83%), Federated Hermes Inc. (0.46%), Northern Trust Corp (0.16%), Sapient Capital LLC (0.11%) and Sapient Capital LLC (0.10%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau.
View institutional ownership trends
.

How do I buy shares of Akebia Therapeutics?

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AKBA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners